Seeking Alpha

Celgene (CELG +0.6%) says it's been notified by the FDA that there won't be an Oncologic Drugs...

Celgene (CELG +0.6%) says it's been notified by the FDA that there won't be an Oncologic Drugs Advisory Committee meeting scheduled for November 8. Its review of the company's NDA  for pomalidomide will continue with the previously announced PDUFA action date of Feb. 10, 2013. Pomalidomide is a potential blockbuster for CELG, and the company has been hoping for an early approval of of the drug to be used in combination with dexamethasone as a treatment for patients with myeloma.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector